[go: up one dir, main page]

AR007897A1 - Un compuesto derivado de la 4-hidroxi-piperidina, su empleo para la elaboracion de un medicamento, un procedimiento para prepararlo, y un medicamento que lo contiene. - Google Patents

Un compuesto derivado de la 4-hidroxi-piperidina, su empleo para la elaboracion de un medicamento, un procedimiento para prepararlo, y un medicamento que lo contiene.

Info

Publication number
AR007897A1
AR007897A1 ARP970103182A ARP970103182A AR007897A1 AR 007897 A1 AR007897 A1 AR 007897A1 AR P970103182 A ARP970103182 A AR P970103182A AR P970103182 A ARP970103182 A AR P970103182A AR 007897 A1 AR007897 A1 AR 007897A1
Authority
AR
Argentina
Prior art keywords
medicinal product
independently
piperidine
lower alkyl
hydroxy
Prior art date
Application number
ARP970103182A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR007897A1 publication Critical patent/AR007897A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/48Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto derivado de la 4-hidroxi-piperidina, de fórmula I en donde X es -O-, -NH-, -CH2-, -CH=, CO2-, -CONH-, -CON (alquilo inferior)-, -S-, Y -SO2-; R1-R4 son independientemente entre sí, hidrógeno, halógeno, hidroxilo, amino, nitro, alquiloinferior-sulfonilamino, 1- o 2-imidazolilo, 1-(1,2,4-triazolil)o acetamido; R5, R6 son, independientemente entre sí, hidrógeno, alquilo inferior, hidroxilo, alcoxilo inferior u oxo; R7, R10 son independientementeentre sí, hidrógeno, alquilo inferior, halógeno, trifluorometilo o alcoxilo inferior; n es 0 o 1; y las sales de adición ácida farmacéuticamente aceptablesde los mismos; su empleo para el tratamiento de enfermedades, un procedimiento para prepararlo y un medicamento que lo contiene. Los compuestos de fórmula Iy sus sales se distinguen por sus valiosas propiedades terapéuticas. Los compuestos de la presente invención son bloqueadores selectivos de los subtiposde receptores del NMDA (N-metil-Daspartato), loscuales tienen una función clave en la actividad y plasticidad neuronal lo cual hace que jueguen un papelbásico en los procesos de mediación que subyacen en el desarrollo del CNS (Sistema nervioso central) así como en la formación de la capacidad deaprendery la memoria.
ARP970103182A 1996-07-19 1997-07-16 Un compuesto derivado de la 4-hidroxi-piperidina, su empleo para la elaboracion de un medicamento, un procedimiento para prepararlo, y un medicamento que lo contiene. AR007897A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96111660 1996-07-19
EP97105366 1997-04-01

Publications (1)

Publication Number Publication Date
AR007897A1 true AR007897A1 (es) 1999-11-24

Family

ID=26142078

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP970103183A AR007898A1 (es) 1996-07-19 1997-07-16 Un compuesto derivado de la 4-hidroxi-piperidina, su empleo para la elaboracion de un medicamento, un procedimiento para prepararlo, y un medicamento que lo contiene.
ARP970103182A AR007897A1 (es) 1996-07-19 1997-07-16 Un compuesto derivado de la 4-hidroxi-piperidina, su empleo para la elaboracion de un medicamento, un procedimiento para prepararlo, y un medicamento que lo contiene.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP970103183A AR007898A1 (es) 1996-07-19 1997-07-16 Un compuesto derivado de la 4-hidroxi-piperidina, su empleo para la elaboracion de un medicamento, un procedimiento para prepararlo, y un medicamento que lo contiene.

Country Status (33)

Country Link
US (1) US5889026A (es)
EP (1) EP0824098B1 (es)
JP (1) JP3179050B2 (es)
KR (1) KR100235804B1 (es)
CN (1) CN1120154C (es)
AR (2) AR007898A1 (es)
AT (1) ATE207899T1 (es)
AU (1) AU719352B2 (es)
BR (1) BR9704031A (es)
CA (1) CA2210044C (es)
CO (1) CO4900064A1 (es)
CZ (1) CZ290898B6 (es)
DE (1) DE69707782T2 (es)
DK (1) DK0824098T3 (es)
ES (1) ES2164967T3 (es)
HR (1) HRP970394A2 (es)
HU (1) HUP9701194A3 (es)
ID (1) ID19632A (es)
IL (1) IL121299A (es)
MA (1) MA24274A1 (es)
MX (1) MX9705387A (es)
NO (1) NO308657B1 (es)
NZ (1) NZ328330A (es)
PE (1) PE86398A1 (es)
PL (1) PL321201A1 (es)
PT (1) PT824098E (es)
RU (1) RU2178412C2 (es)
SG (1) SG60085A1 (es)
TR (1) TR199700659A2 (es)
TW (1) TW498067B (es)
UY (1) UY24625A1 (es)
YU (1) YU30197A (es)
ZA (1) ZA976224B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
US6339087B1 (en) 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
MXPA00011889A (es) * 1998-06-02 2003-04-25 Osi Pharm Inc Composiciones de pirrolo (2,3d) piridina y su uso.
CO5150201A1 (es) * 1998-09-07 2002-04-29 Hoffmann La Roche Derivados de piperidina
ATE386720T1 (de) 1998-11-20 2008-03-15 Hoffmann La Roche Piperidin ccr-3 rezeptor-hemmer
TWI254043B (en) * 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor
US6432985B2 (en) * 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
PA8525601A1 (es) 2000-08-21 2002-04-25 Hoffmann La Roche Profarmacos de (3s,4s)-4-bencil-1-[2-(4-hidroxi-bencenosulfonil)-etil]-piperidin-3-ol
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
US6680324B2 (en) * 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
WO2002072542A2 (en) * 2001-03-08 2002-09-19 Emory University Ph-dependent nmda receptor antagonists
DK1409477T3 (da) * 2001-07-24 2008-12-08 Richter Gedeon Nyrt Piperdinderivater som NMDA receptorantagonister
WO2003048120A2 (en) * 2001-11-30 2003-06-12 Osi Pharmaceuticals, Inc. 2-aryl pyrrologpyrimidines for a1 and a3 receptors
WO2003053366A2 (en) * 2001-12-20 2003-07-03 Osi Pharmaceuticals, Inc. Pyrimidine a2b selective antagonist compounds, their synthesis and use
US6951884B2 (en) * 2002-06-12 2005-10-04 Hoffmann-La Roche Inc. Fluorobenzamides and uses thereof
WO2005030720A1 (ja) * 2003-09-25 2005-04-07 Shionogi & Co., Ltd. Nmda受容体拮抗作用を有するピペリジン誘導体
EP1680127B1 (en) * 2003-10-23 2008-10-15 F. Hoffmann-La Roche Ag Benzazepine derivatives as mao-b inhibitors
HUP0401522A2 (en) * 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
US7485637B2 (en) * 2005-01-04 2009-02-03 Hoffmann-La Roche Inc. Benzoyl-tetrahydropiperidine derivatives
CN101815518B (zh) 2007-06-29 2013-01-09 埃莫里大学 用于神经保护的nmda受体拮抗剂
US7869022B2 (en) 2007-07-18 2011-01-11 Asml Netherlands B.V. Inspection method and apparatus lithographic apparatus, lithographic processing cell, device manufacturing method and distance measuring system
SG195568A1 (en) * 2008-05-09 2013-12-30 Univ Emory Nmda receptor antagonists for the treatment of neuropsychiatric disorders
US7874106B2 (en) * 2009-02-13 2011-01-25 Ykk Corporation Of America Sill flashing and end dam assembly
WO2011049737A1 (en) * 2009-10-19 2011-04-28 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating lysosomal storage disorders
KR101880411B1 (ko) * 2009-10-19 2018-07-19 아미쿠스 세라퓨틱스, 인코포레이티드 중추신경계의 퇴행성 질환을 예방 및/또는 치료하는 신규 조성물
EP3233799B1 (en) 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamine d2 receptor ligands
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU61061A1 (ru) * 1940-11-27 1941-11-30 И.И. Петров Прибор дл увлажнени и дезодорации воздуха
US3850935A (en) * 1971-10-16 1974-11-26 Sumitomo Chemical Co Process for producing piperidine derivatives by degrading quaternary piperidinium salts
US5356905A (en) * 1990-02-06 1994-10-18 Pfizer Inc. Neuroprotective 3-piperidino-4-hydroxychroman derivatives and analogs
FR2672286B1 (fr) * 1991-01-31 1994-11-18 Synthelabo Derives de 1-(4-chlorophenyl)-2-[4-(phenylmethyl)piperidin-1-yl]ethanol, leur preparation et leur application en therapeutique.
FR2681319B1 (fr) * 1991-09-12 1995-02-17 Synthelabo Derives de 1-(phenoxyalkyl)piperidine, leur preparation et leur application en therapeutique.
TW281670B (es) * 1993-09-02 1996-07-21 Hoffmann La Roche
DE69420053T2 (de) * 1994-01-31 1999-11-25 Pfizer Inc., New York Neuroprotektive chroman verbindungen
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610736B (en) * 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists

Also Published As

Publication number Publication date
CO4900064A1 (es) 2000-03-27
JPH1067742A (ja) 1998-03-10
ES2164967T3 (es) 2002-03-01
CA2210044C (en) 2006-02-14
HRP970394A2 (en) 1998-06-30
ATE207899T1 (de) 2001-11-15
PT824098E (pt) 2002-04-29
DK0824098T3 (da) 2002-02-18
NO308657B1 (no) 2000-10-09
KR100235804B1 (ko) 1999-12-15
AU719352B2 (en) 2000-05-04
EP0824098B1 (en) 2001-10-31
YU30197A (sh) 1999-12-27
ZA976224B (en) 1998-01-19
DE69707782T2 (de) 2002-06-20
US5889026A (en) 1999-03-30
DE69707782D1 (de) 2001-12-06
TR199700659A2 (xx) 1998-02-21
IL121299A (en) 2001-12-23
KR980009244A (ko) 1998-04-30
BR9704031A (pt) 1998-12-29
AU2875697A (en) 1998-01-29
RU2178412C2 (ru) 2002-01-20
UY24625A1 (es) 2000-12-29
HUP9701194A3 (en) 1999-06-28
NZ328330A (en) 1998-05-27
NO973337D0 (no) 1997-07-18
NO973337L (no) 1998-01-20
PE86398A1 (es) 1998-12-10
HK1009124A1 (en) 1999-05-28
CZ227497A3 (cs) 1998-02-18
CN1120154C (zh) 2003-09-03
CA2210044A1 (en) 1998-01-19
AR007898A1 (es) 1999-11-24
CN1171396A (zh) 1998-01-28
HU9701194D0 (en) 1997-09-29
IL121299A0 (en) 1998-01-04
CZ290898B6 (cs) 2002-11-13
HUP9701194A2 (hu) 1999-05-28
JP3179050B2 (ja) 2001-06-25
PL321201A1 (en) 1998-02-02
TW498067B (en) 2002-08-11
EP0824098A1 (en) 1998-02-18
ID19632A (id) 1998-07-23
SG60085A1 (en) 1999-02-22
MX9705387A (es) 1998-01-31
MA24274A1 (fr) 1998-04-01

Similar Documents

Publication Publication Date Title
AR007897A1 (es) Un compuesto derivado de la 4-hidroxi-piperidina, su empleo para la elaboracion de un medicamento, un procedimiento para prepararlo, y un medicamento que lo contiene.
KR102139537B1 (ko) Lsd1 억제제로서 (헤테로)아릴 사이클로프로필아민 화합물
UY27592A1 (es) Nuevo uso
MXPA04005444A (es) Ureas de 2-aminobenzotiazoles como moduladores de adenosina.
AR035422A1 (es) Compuestos derivados de imidazol, un medicamento que contiene uno o mas de dichos compuestos, un proceso para la preparacion de dichos compuestos y uso de dichos compuestos.
CO4290424A1 (es) Pirazolopiridinas, pirrolopiridinas, composiciones farmaceu- ticas que las contienen y procedimientos para su administra- cion como antagonista del factor de liberacion de cortico- tropina
MXPA04005209A (es) Antagonistas del receptor de adenosina a2a.
RU94045155A (ru) Способы ингибирования болезни альцгеймера
AR029454A1 (es) Derivados de piperazina sustituidos, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos
CA3014740C (en) 2,3,5-substituted thiophene compound as protein kinase inhibitor
TNSN97055A1 (fr) Derives de 6-phenylpyridyl -2- amine, procede pour leur preparation et compositions pharmaceutiques les contenant.
ES2160525B1 (es) Derivados de la 4-aroilpiperidina antagonistas de los receptores ccr-3
NZ514487A (en) Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands
ZA200206956B (en) Derivatives of quinoline as alpha-2 antagonists.
ATE57922T1 (de) Gegebenenfalls substituierte, 1-(2'-(bis-(phenyl)-methoxy>-aethyl)-4-(3'-(bisphenyl)-methoxy>- propyl)-piperazine, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
CA3135409A1 (en) Pyrrolopyrimidine inhibitors of wild-type and mutant forms of lrrk2
AR037221A1 (es) Compuestos derivados de piridina, uso de los mismos, un procedimiento para su preparacion y un medicamento que contiene uno o mas de dichos compuestos
AR032601A1 (es) UN COMPUESTO DERIVADO DE QUINOLIN -4-IL, MEDICAMENTO QUE CONTIENE UNO O MAS DE DICHO COMPUESTO, PROCEDIMIENTO PARA LA PREPARACIoN DEL COMPUESTO Y EL USO DEL COMPUESTO
KR102023748B1 (ko) 순수한 5-ht6 수용체 길항제 및 nmda 수용체 길항제의 조합물
KR102016120B1 (ko) 순수한 5-ht6 수용체 길항제, 아세틸콜린에스테라제 저해제 및 nmda 수용체 길항제의 3중 조합물
CA2421936A1 (en) (2-azabicyclo[2.2.1]hept-7-yl)methanol derivatives as nicotinic acetylcholine receptor agonists
DK557189D0 (da) 1,2,3,4-tetrahydro-1,9-acridindiaminer, deres fremstilling og anvendelse som laegemidler
HUP0303253A2 (hu) Aril-karbamát-származékok, eljárás előállításukra és alkalmazásuk
AR008095A1 (es) Indanilidinacetilguanidinas sustituidas, procedimiento para su preparacion, su uso en la preparacion de medicamentos o agentes de diagnosticoasi como medicamento que las contienen
TW201802093A (zh) 動物及人類抗錐蟲及抗利什曼原蟲藥劑

Legal Events

Date Code Title Description
FG Grant, registration